<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) is one of the most common causes of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related <z:hpo ids='HP_0011420'>deaths</z:hpo> in western countries </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> are commonly divided in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> showing microsatellite stability (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e>) or microsatellite instability (MSI) </plain></SENT>
<SENT sid="2" pm="."><plain>A more novel classification is dependent on promoter hypermethylation of CpG islands (the CpG island methylator phenotype, CIMP), where <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> show high, low or negative methylation status </plain></SENT>
<SENT sid="3" pm="."><plain>SMAD4, located on chromosome 18q, has been thoroughly investigated during the last years </plain></SENT>
<SENT sid="4" pm="."><plain>Loss of SMAD4 expression has been reported to correlate with poor <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patient prognosis </plain></SENT>
<SENT sid="5" pm="."><plain>In this study, we analyze the impact of SMAD4 expression on prognosis in relation to MSI screening status and CIMP status </plain></SENT>
<SENT sid="6" pm="."><plain>Four hundred and seventy-nine paraffin-embedded specimens of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> were examined for nuclear SMAD4 expression using immunohistochemistry </plain></SENT>
<SENT sid="7" pm="."><plain>The <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> were scored loss (-), moderate (+) and high (++) expressing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Loss of SMAD4 correlated significantly with decreased survival in <z:hpo ids='HP_0000001'>all</z:hpo> <z:hpo ids='HP_0003003'>colon cancer</z:hpo> patients </plain></SENT>
<SENT sid="9" pm="."><plain>High SMAD4 expression, however, was significantly associated with increased survival, especially in <z:hpo ids='HP_0003003'>colon cancer</z:hpo> patients, which has undergone potential curative surgery </plain></SENT>
<SENT sid="10" pm="."><plain>In addition, in MSI <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and CIMP-high <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, high SMAD4 expression was significantly related to increase in survival, while loss of SMAD4 resulted in a significantly poorer prognosis </plain></SENT>
<SENT sid="11" pm="."><plain>SMAD4 expression was not correlated to prognosis in <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> cases </plain></SENT>
<SENT sid="12" pm="."><plain>We conclude, loss of SMAD4 indicates a poor prognosis in <z:hpo ids='HP_0003003'>colon cancer</z:hpo> patients </plain></SENT>
<SENT sid="13" pm="."><plain>The novel findings that high SMAD4 expression predicts a better prognosis suggests that SMAD4 immunohistochemistry could constitute a prognostic marker in combination with CIMP and MSI screening status </plain></SENT>
</text></document>